Edinburgh Biosciences (EBS) has signed a major international licensing and equity investment deal in China, as the company aims to take cataract treatment from the operating theatre to the high street. The licensing deal is with China’s Haoguang, a wholly-owned subsidiary of Boye Biotech.
Edinburgh Biosciences
1-1 of 1 Articles